Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • Certolizumab Pegol for...

    Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis-Phase 3 Trial Report

    Written by Vinay Singh singh Published On 2018-08-23T19:25:20+05:30  |  Updated On 23 Aug 2018 7:25 PM IST
    Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis-Phase 3 Trial Report

    Treatment with either certolizumab 400 mg or 200 mg every 2 weeks was associated with significant and clinically meaningful improvements in moderate-to-severe psoriasis, according to the results of two phase III trials, CIMPASI-1 and CIMPASI-2 published in the Journal of the American Academy of Dermatology (JAAD).


    Certolizumab pegol, is the only Fc-free, PEGylated anti-tumor necrosis factor biologic. Consequently, it is not expected to undergo FcRn-mediated transfer across the placenta, showing the minimal placental transfer of CZP from mothers to infants.


    Alice B. Gottlieb et al. conducted the 2 phase 3 trials CIMPASI-1 and CIMPASI-2, to evaluate the efficacy and safety of CZP compared with placebo in the treatment of moderate-to-severe chronic plaque psoriasis.


    Read Also:Topical use of Halobetasol ,Tazarotene combo offers better results in Psoriasis


    Patients with moderate-to-severe chronic plaque psoriasis were randomized 2:2:1 to certolizumab 400 mg, certolizumab 200 mg, or placebo every 2 weeks. The primary outcome was week 16 responder rates, defined as a 75% reduction in Psoriasis Area and Severity Index and Physician's Global Assessment 0/1 (clear/almost clear).


    Key study findings:




    • Treatment with CZP 400 mg or 200 mg every 2 weeks led to significantly greater PASI 75, PGA 0/1, and PASI 90 responder rates at week 16 than treatment with placebo in patients with moderate-to-severe chronic plaque psoriasis.

    • At week 16 in CIMPASI-2, PASI 100 responder rates were 18.8% for CZP 400 mg every 2 weeks, 15.4% for CZP 200 mg every 2 weeks, and 1.8% for placebo, and by week 48, they improved to 38.3% and 31.4% for CZP 400 mg every 2 weeks and CZP 200 mg every 2 weeks, respectively.

    • Pooled data for PASI 100 showed responder rates of 14.4% for CZP 400 mg every 2 weeks, 12.7% for CZP 200 mg every 2 weeks, and 0.9% for placebo through week 16.

    • At week 48, PASI 100 response rates in the pooled population were 34.5% for CZP 400 mg every 2 weeks and 28.5% for CZP 200 mg every 2 weeks.


    The study concluded that compared with treatment with placebo, treatment with either CZP dose was also associated with significant and clinically meaningful improvements in health-related quality of life through week 16, which was maintained through week 48.


    Psoriasis is a common chronic, immune-mediated inflammatory disease. Patients with more severe psoriasis are often treated with systemic medications, phototherapy, and biologic agents, but not all patients tolerate or respond to currently available therapies, and some might have contraindications.


    For reference log on to https://doi.org/10.1016/j.jaad.2018.04.012

    certolizumabchronicCIMPASI 2CIMPASI1CZPJAADJournal of the American Academy of DermatologyphototherapyplacentaplaquepsoriasisQuality of lifeSeverity Index
    Source : With inputs from Journal of the American Academy of Dermatology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok